Stokle

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stokle

What is Stokle?

Stokle is a pharmaceutical medication containing the active ingredient sitogliptin. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. This medication is primarily used in the management of type 2 diabetes mellitus to help control blood glucose levels.

Mechanism of Action

The active component, sitogliptin, works by regulating the levels of insulin the body produces after eating. It functions by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones. By preventing the breakdown of these hormones, Stokle increases the release of insulin from the pancreas and decreases the production of glucagon by the liver. These actions collectively assist in maintaining more stable blood sugar levels throughout the day.

Therapeutic Use

Stokle is utilized as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It may be prescribed as a monotherapy or in combination with other glucose-lowering medications, such as metformin or sulfonylureas, when a single agent does not provide sufficient blood sugar management. Unlike some other diabetes treatments, sitogliptin is glucose-dependent, meaning it primarily works when blood sugar levels are elevated, which reduces the likelihood of blood sugar dropping too low during routine use.

Clinical Role

As a DPP-4 inhibitor, Stokle offers an oral treatment option for patients who require assistance in managing their hemoglobin A1c (HbA1c) levels. Effective management of blood glucose is a central component in reducing the long-term health complications associated with persistent hyperglycemia in individuals with type 2 diabetes.

Regulatory References

  1. Dimethicone (Topical Products) - DailyMed

What side effects are possible with Stokle?

Possible Side Effects and Safety Information

The safety profile of Dimethicone (Stokle) is largely determined by its classification as a pharmacologically inert compound that is not absorbed systemically, according to official government regulatory documentation. This results in an adverse reaction profile that is primarily localized to the site of application or action.


Documented Adverse Reactions and Safety Concerns

The documented adverse reactions are categorized based on the route of administration, as listed in authoritative sources like the FDA's DailyMed and NIH documents.

Classification Topically (Skin Protectant) Orally (Antifoaming Agent)
System-Organ Class Skin and Subcutaneous Tissue Disorders Gastrointestinal Disorders
Expected Reactions Localized effects such as redness, burning, stinging, itching, or unusual changes in the skin like softening. Mild, non-persistent effects such as nausea or mild diarrhea.

Serious Adverse Reactions and Regulatory Constraints

Official regulatory sources note that while the drug is non-absorbed, the most significant risk is the rare occurrence of a serious allergic reaction. Signs of such a reaction, defined as a potentially fatal event, include difficulty breathing, wheezing, tightness in the throat, or swelling of the face, lips, or tongue.

Regulatory documents define strict limitations for the topical product, which should not be used on puncture wounds, infections, lacerations, or areas affected by eczema or dermatitis. Furthermore, non-systemic safety notes suggest that the oral form may potentially change the absorption of other oral medications, a regulatory consequence requiring documentation.

Overdose and Emergency Response

Overdose Profile: Official Regulatory Information

The regulatory profile for Stokle overdose is based on the classification of its active ingredient, Dimethicone, as a pharmacologically inert and non-absorbed compound. This non-systemic property dictates the officially documented overdose presentation. No specific systemic signs, symptoms, or physiological findings are formally documented in regulatory labeling due to the lack of internal absorption.

Feature Regulatory Documentation Status
Systemic Manifestations Not documented; drug is non-absorbed.
Life-Threatening Outcomes No serious or life-threatening systemic effects are documented or expected.
Antidote No specific pharmacological antidote is known.
Management Treatment is limited to symptomatic and supportive care.

When to Seek Immediate Medical Help

The primary regulatory requirement for suspected overdose relates to the need for immediate professional assessment, regardless of symptoms. The official guidance uniformly mandates:

Emergency-Response Statement (Label-Derived Phrasing): In case of overdose, get medical help or contact a Poison Control Center immediately. Quick medical attention is critical even if you do not notice any signs or symptoms.

Official Overdose Context: Overdose exposure is defined as use exceeding the maximum dosage instructions. The official warning also includes the explicit mandate that the product must be kept out of reach of children.

Therapeutic Uses of Stokle

Quick Facts: Therapeutic Domains

  • Targeted Condition: Dravet syndrome
  • Therapeutic Role: Adjunctive treatment to address seizure frequency
  • Potential Benefit: May help improve overall seizure control and clinical status

Stokle is a pharmaceutical agent under investigation for use as an adjunctive therapy in the management of Dravet syndrome, a severe and progressive form of genetic epilepsy. The medication is intended for individuals with this condition who are candidates for systemic therapy.

The primary therapeutic aim of Stokle is to provide support for improving the control of seizures associated with Dravet syndrome. The agent has demonstrated activity consistent with its proposed role in reducing the frequency of convulsive seizures. The treatment is part of a comprehensive care plan aimed at potentially leading to continuous improvements in the overall clinical status of the patient.

Stokle is also being evaluated for its potential to address non-seizure-related aspects of the disease, such as certain measures of cognition and behavior. The medication has received a Breakthrough Therapy Designation for its use in this condition. This designation supports the advancement of its development as a potential treatment option.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Stokle

The official eligibility profile for Stokle (Dimethicone) is largely determined by its classification as a non-systemically absorbed medicine, resulting in minimal constraints based on the body’s internal functions.

Eligibility Status Specific Regulatory Statement
Contraindicated The medicine is contraindicated in patients with a known hypersensitivity or allergy to Dimethicone, Simethicone, or any component in the formulation.
Eligibility Restriction Topical formulations must not be applied to deep or puncture wounds, animal bites, or serious burns. Oral forms are not recommended for use solely for the treatment of infant colic.

Age and Condition Rules

Eligibility Status Specific Regulatory Statement
Age-Group Use Use is permitted for adults, teenagers, children, and infants. Some specific topical product labeling advises against use in children under the age of two years. No unique restrictions are documented for older adults.
Systemic Impairment No official restrictions are documented for patients with renal impairment or hepatic impairment due to the drug’s non-systemic nature.
Maternal Status Use is considered acceptable during pregnancy and lactation. Significant transfer to the fetus or breast milk is not expected due to lack of systemic absorption.

Connection to the overall eligibility profile

Regulatory documents establish that exclusion from using Stokle is primarily limited to a documented allergy to the ingredients or the compromised physical state of the application site. Otherwise, the medicine is classified as generally eligible across all major age groups and patients with systemic organ conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Stokle (Dimethicone) consistently confirms a minimal to absent potential for systemic drug interaction. This profile is defined by the compound's nature as a pharmacologically inert substance that undergoes minimal or no systemic absorption following either oral or topical administration.

Official Interaction Profile

Interaction Type Regulatory Status
Contraindicated Combinations None documented.
Pharmacokinetic Interactions (e.g., CYP Enzymes) None documented due to non-systemic activity.
Transporter-Mediated Interactions (e.g., P-gp) None documented.
Pharmacodynamic Interactions None documented due to pharmacological inertness.
Food, Alcohol, or Herbal Products No known interactions.

Regulatory authorities confirm that the absence of systemic activity eliminates the need for documented restrictions regarding co-administration. Prescribing information does not list any mandatory timing-based administration rules (e.g., separation by hours) or substances that are formally contraindicated based on systemic interaction risk. Furthermore, there are no documented interactions that modify the exposure or clearance of Stokle (Dimethicone) or that require specific cautions in patient subpopulations like those with liver impairment. The final regulatory classification is defined by the absence of known significant systemic interactions.

Mechanism of Action

Antisense Oligonucleotide Mechanism

Stokle is an antisense oligonucleotide (ASO) therapy that targets gene expression within the central nervous system. The drug is delivered to neurons where it is designed to bind specifically to the messenger RNA (mRNA) transcribed from the non-mutant (wild-type) copy of the SCN1A gene. This interaction leverages a proprietary mechanism called Targeted Augmentation of Nuclear Gene Output (TANGO), which modulates naturally occurring non-productive splicing events.


Molecular Cascade and Protein Expression

The ASO binding event prevents the inclusion of a non-productive, nonsense-mediated decay (NMD)-inducing exon (often referred to as a poison exon) into the final SCN1A transcript. By converting these non-productive transcripts into productive mRNA, Stokle leads to an increase in the total amount of functional SCN1A mRNA. This increased mRNA is subsequently translated into a higher concentration of the corresponding protein, the voltage-gated sodium channel Na V1.1.


System-Level Physiological Consequence

The primary physiological effect of increased Na V1.1 protein concentration is the modulation of neuronal excitability. Na V1.1 channels are predominantly expressed in GABAergic inhibitory interneurons. Augmenting channel availability in these interneurons enhances their function, thereby influencing the balance of electrical signaling within neural networks and modifying the frequency of action potentials.

Dosage and Administration Information

How to Use Stokle

Stokle (Dimethicone/Simethicone) administration is defined by two separate, non-systemic usage pathways. The instructions below detail the administration for topical (skin protectant) and oral (antigas) use.

Feature Topical Use (Skin Protectant) Oral Use (Antigas Agent)
Route of Administration Topical (Strictly for external use). Oral (Taken by mouth).
Dosing Schedule Apply liberally to the affected area. Concentrations range from 1 % to 30 % in the final product. Adult doses (ge 12 years) are typically 125 mg to 250 mg per single symptomatic need.
Timing & Frequency Applied as often as needed (symptomatic use). Taken as needed after meals and again at bedtime.
Age-Group Administration Applied as needed for all ages. Infants (< 2 years): 0.3 mL. Children (ge 2 years): 0.6 mL. Do not exceed 12 doses per 24 hours.

Preparation and Procedural Conditions

Guidelines require specific steps to ensure proper administration:

  • Preparation: Oral suspensions (drops) must be shaken well prior to measuring the dose.
  • Procedural Condition: Chewable tablets must be chewed completely before swallowing. Oral administration must not exceed the established 24-hour maximum dose limit for the specific form being used.

Connection to the Overall Use Protocol

The administration protocol is defined by an as-needed frequency for symptomatic relief, distinguishing it from fixed maintenance therapies. This structure requires adherence to strict intake methods, such as chewing or shaking, and adherence to the established age-specific volume rules for pediatric liquid administration, ensuring standardized use.

Recent Clinical Evidence

Stokle: Recent Clinical Evidence

Clinical research has focused on the investigational compound zorevunersen (formerly STK-001) for the potential treatment of Dravet syndrome, a severe form of genetic epilepsy. Studies have been conducted in children and adolescents, typically alongside patients’ existing anti-seizure medications. The compound is currently being evaluated in a pivotal Phase 3 study (EMPEROR).


Overview of Findings from Phase 1/2a and Open-Label Extension (OLE) Studies

Phase 1/2a and OLE studies primarily investigated the safety profile and measured changes in seizure frequency and non-seizure-related outcomes over time. The most substantial observations regarding major motor seizure frequency were made in cohorts receiving the highest initial doses (70 mg).

Outcome Category Observations Recorded in OLE Studies (Up to 3 Years)
Seizure Frequency Substantial and durable reductions in major motor seizure frequency were recorded, with median reductions in the highest-dose cohorts reaching approximately 85% at 3 months post-initial dosing.
Cognition & Behavior Continuous improvements were tracked in multiple measures of cognition and adaptive behavior, as evaluated using standard assessment scales (e.g., Vineland-3 subdomains).

Safety and Tolerability

Across the studies, the investigational compound was generally noted to be well-tolerated. The most common adverse events related to the study drug included elevated cerebrospinal fluid (CSF) protein levels and procedural vomiting. CSF protein elevations were observed in a high percentage of patients, particularly in the OLE studies, though these laboratory findings were generally not associated with related clinical symptoms. One patient was reported to have discontinued treatment due to elevated CSF protein levels.

Key Studies & References

  1. EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
  2. Zorevunersen demonstrates potential for disease modification including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet Syndrome (DS) - Phase 1/2a Study Data

Frequently Asked Questions (FAQ)

Common questions about Stokle (FAQ)


Q: What is Stokle prescribed for most often?

A: Official documents define Stokle (Dimethicone) with two main purposes: to act as a Skin Protectant when applied externally, or as an Antifoaming Agent when taken orally to relieve excess gas and bloating. Regulatory documentation does not specify which of these two uses is the more frequent reason for prescription or use by patients.

Q: Does Stokle start working right away?

A: Stokle is classified for 'as-needed' symptomatic relief because its mechanism of action is physical and localized, meaning it doesn't need to be absorbed into the bloodstream. While official information does not specify an exact onset time in minutes, the effects are generally described as rapid due to its direct action on gas bubbles in the digestive tract.

Q: How long does it usually take to notice the effects of Stokle?

A: The drug is structured for symptomatic relief, suggesting effects should be noticeable when relief is needed. Regulatory administration guidance, detailed in the 'How to use' section, includes procedural conditions (like chewing or shaking liquids) intended to support the drug's effectiveness. Regulatory labeling focuses on its quick, physical action rather than a specific duration of effect.

Q: What are the most commonly reported side effects of Stokle?

A: Stokle is generally considered to be well-tolerated because it is not absorbed systemically into the body. The most commonly reported side effects are mild, localized reactions, such as mild diarrhea or nausea for the oral form, or minor skin irritation for the topical products. Official regulatory sources do not typically provide quantified rates or statistics on the frequency of these reactions.

Q: Is it normal to feel a bit nauseous when starting Stokle?

A: Nausea is noted in official regulatory information as a possible, non-persistent side effect associated with the oral form of Stokle. The product information does not specify if this feeling is more common when first starting the medication versus continuing use. If nausea persists or is severe, review of the symptom status with a healthcare professional is appropriate.

Q: Can drinking caffeine affect how Stokle works?

A: Regulatory documents consistently confirm that Stokle (Dimethicone) has a low potential for systemic drug interactions because it is pharmacologically inert. Therefore, official product information indicates no known interactions with food, alcohol, or herbal products, which includes caffeine.

Q: What should I do if the side effects of Stokle feel severe?

A: Official regulatory safety guidance states that the most significant risk is the rare occurrence of a serious allergic reaction. Signs such as difficulty breathing, wheezing, throat tightness, or severe swelling of the face are described as serious events. In the event of signs consistent with a severe or concerning reaction, seeking immediate professional medical help is indicated based on regulatory safety information.

Q: Is Stokle a drug that is easy to stop taking?

A: Because Stokle is non-systemically absorbed and is taken on an 'as-needed' basis for symptomatic relief, it is not associated with dependency. The drug's usage profile and non-systemic classification mean regulatory labeling does not include instructions for discontinuation or concerns about withdrawal effects.

Q: What is the risk of developing a dependency on Stokle?

A: Official regulatory information describes the active ingredient in Stokle, Dimethicone, as a pharmacologically inert substance that is not absorbed into the body's systems. This chemical profile means there is no known potential for dependency or abuse documented in official sources.

Q: Can Stokle cause allergic reactions?

A: Yes, official safety information indicates that allergic reactions are possible with Stokle or any component in its formulation. These reactions can range from mild effects like rash and itching to a rare, serious systemic event requiring medical attention, as noted in authoritative sources.

Q: Why does the medication guide advise caution for people with glaucoma?

A: The official regulatory profile for Stokle as a single-ingredient, non-systemic agent does not list glaucoma as a specific contraindication for use. Caution regarding glaucoma is generally associated with prescription combination products that contain systemic ingredients that could affect the eyes, not the single-active ingredient in Stokle.

Q: Is Stokle used for chronic conditions?

A: Official regulatory guidance defines Stokle’s utility as providing 'as-needed' symptomatic relief for excess gas, or acting as a physical skin barrier. The current regulatory approval is not defined as a fixed maintenance treatment for a specific chronic underlying condition.

Q: Why does Stokle have to be taken regularly?

A: Official regulatory guidance defines the use of Stokle as an 'as-needed' frequency for symptomatic relief, rather than as a medication that must be taken regularly. Therefore, the frequency of intake is determined by the patient’s symptoms and need, not a fixed schedule.

Q: Is Stokle known to cause weight changes?

A: Due to its nature as a pharmacologically inert substance that is not systemically absorbed, regulatory documents do not list or describe weight change as a reported side effect or consequence of using Stokle.

Q: Can Stokle cause problems with sleep?

A: Regulatory documents for the single-ingredient product do not list any effects on the central nervous system, such as drowsiness or sleeplessness. This is consistent with the drug's non-systemic safety profile, meaning it does not get absorbed to affect brain function.

Q: Are there any long-term effects of taking Stokle that are documented?

A: The safety profile of Stokle is established on its non-systemic and inert nature, which minimizes the potential for systemic exposure. Official regulatory documents indicate a minimal risk for systemic long-term effects, as this low risk is consistent with its non-systemic nature, meaning it is not absorbed into the body.

Q: Does Stokle require special monitoring or blood tests?

A: Due to the non-systemic nature of the drug, the official regulatory profile for Stokle (Dimethicone) does not list any mandatory special laboratory tests or specific patient monitoring requirements during its use.

Q: Have there been long-term studies published about Stokle?

A: The active ingredient in Stokle has been in wide use for many decades, and its safety is based on its non-systemic classification. Regulatory documentation relies on this established safety profile and generally does not cite specific published long-term studies for this type of over-the-counter ingredient.

Q: Where can I find the official regulatory information about Stokle?

A: Official regulatory information can be accessed through government-run databases such as the U.S. National Institutes of Health (NIH) MedlinePlus or the Food and Drug Administration (FDA) DailyMed service. This information is typically listed under the active ingredient name.

Q: Can Stokle be taken while driving or operating machinery?

A: Because Stokle is not systemically absorbed and does not cause central nervous system effects, official regulatory guidance indicates it is generally considered not to affect a person’s ability to drive or operate machinery.

Q: Is Stokle approved in other countries besides the US?

A: The active ingredient in Stokle, Dimethicone (Simethicone), is a well-established compound approved and regulated by governmental bodies in many regions worldwide. These include major regulatory agencies in Europe (EMA), Canada (Health Canada), and Australia (TGA).

Q: Are generic versions of Stokle available?

A: The active ingredient in Stokle, Dimethicone (Simethicone), is an over-the-counter compound that is widely available in many generic formulations and brands. These are listed in general regulatory databases that track approved drug products.

Q: What is the maximum duration for which Stokle is typically prescribed?

A: Official regulatory guidance defines Stokle as an 'as-needed' treatment for symptomatic relief, with only a maximum dose limit per 24 hours. The documentation does not define a mandatory stop date or maximum number of months or years for use.

Q: Are there any common reasons why Stokle might be stopped by a healthcare provider?

A: A healthcare provider may advise stopping Stokle if symptoms of excess gas or skin irritation persist or worsen while using the product. Discontinuation is also necessary if a patient experiences signs of a severe allergic reaction.

Q: Does the time of day matter when taking Stokle?

A: Official labeling for the oral form recommends taking Stokle after meals and at bedtime for symptomatic gas relief. No specific regulatory restriction is placed on taking the product at a particular time of day; the timing is generally linked to symptomatic need and food intake.

Q: How common are serious side effects from Stokle?

A: Serious adverse events, such as a severe allergic reaction, are officially described as a 'rare' or 'extremely rare' occurrence based on the established safety profile of the active ingredient. This low incidence is related to the drug's non-systemic nature.

Q: Does Stokle affect hormone levels?

A: Due to its characterization as a non-systemically absorbed and pharmacologically inert compound, official regulatory documents do not indicate that Stokle affects hormone levels or endocrine function.

Q: Is Stokle ever used in combination with other prescription treatments?

A: Stokle (Dimethicone) has a low potential for systemic interactions and is often used alongside other treatments. For example, it may be included in preparations used to clear the bowel prior to medical procedures, or used with common prescription medicines.

How should Stokle be stored and disposed of?

Stokle tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, tightly closed, and protected from excess heat, moisture, and direct light. It is mandatory to keep Stokle out of the sight and reach of children. Tablets must not be crushed, cut, or chewed. If a tablet is broken, handling requires wearing protective gloves to avoid dermal exposure; pregnant women must avoid handling compromised tablets. Unused or expired medication must not be flushed down a toilet or discarded in household trash due to its nature as a hazardous drug. Disposal must follow special procedures through an authorized waste collection program as advised by a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stokle found in:

A-Z Index: